Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Healthcare Biotechnology
Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in... see more

Recent & Breaking News (TSXV:BTI.H)

Bioasis Strengthens Senior Management Team with Appointment of Caroline Dircks, Ph.D. as Chief Operating Officer

Business Wire August 15, 2019

Bioasis Announces Filing of Its Quarterly Financial Statements and MD&A for the Period Ending May 31, 2019

Business Wire July 26, 2019

Bioasis Announces Stock Option Grants

Business Wire July 17, 2019

Bioasis Announces FDA Response to Pre-IND Submission

Business Wire June 25, 2019

Bioasis Announces Allowances of Patent Applications in the U.S. and Europe Relating to xB3 Platform Technology and Key Therapeutic Indications

Business Wire June 24, 2019

Bioasis Appoints Mario Saltarelli as Non-Executive Director of the Board of Directors

Business Wire May 30, 2019

Bioasis Announces Closing of Previously Disclosed Private Placement

Business Wire May 21, 2019

Bioasis Announces Private Placement

Business Wire May 6, 2019

Bioasis Technologies Inc. Announces Warrant Extension

Business Wire March 25, 2019

Bioasis Appoints Dr. Deborah Rathjen as President & Chief Executive Officer

Business Wire March 11, 2019

Bioasis Announces Filing of Its Quarterly Financial Statements and MD&A for the Period Ending November 30, 2018

Business Wire January 29, 2019

Bioasis Announces the Appointment of Christine Antalik as Chief Financial Officer

Business Wire January 9, 2019

Bioasis Announces Agreement With Leading Pharmaceutical Company for Pre-Clinical Research Using the xB3 Platform Technology

Business Wire January 7, 2019

Bioasis to Present at Investor & Industry Conferences in January 2019

Business Wire December 13, 2018

Bioasis Appoints Dr. Deborah A. Rathjen as Executive Chair of the Board of Directors

Business Wire December 10, 2018

Bioasis Announces Voting Results for 2018 Annual and Special Meeting

Business Wire November 26, 2018

Bioasis Announces Positive Results from Peripheral Whole-Body PET/CT Scan Study in Non-Human Primates with Lead Investigational Candidate xB3-001TM

Business Wire November 20, 2018

Bioasis Announces Filing of Its Quarterly Financial Statements and MD&A for the Period Ending August 31, 2018

Business Wire October 30, 2018

Bioasis Announces xB3 ™ Platform Technology Licensing Agreement with Prothena

Business Wire October 29, 2018

Bioasis Announces Investor Relations Service Agreement with Stern IR

Business Wire October 4, 2018